Skip to content

Dentsply Sirona

US · XRAY #2904 by market cap Listed 1970
8.29 -0.20 -2.36%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Valuation each multiple against its own 5-year range

P/B ratio 1.34 Cheap vs history 8th percentile
5-year average 1.78 · #10 of 51 in Medical Instruments & Supplies
P/E ratio -15.02 Cheap vs history 21st percentile
5-year average -7.22 · forward 33.00
P/S ratio 0.51 Cheap vs history 2nd percentile
5-year average 1.42 · forward 0.52 · #7 of 51 in Medical Instruments & Supplies

Vs. peers Medical Instruments & Supplies

Company Market cap P/E (TTM) P/B Div yield
Dentsply Sirona (XRAY) 1.64B -13.59 1.21 1.93%
Intuitive Surgical (ISRG) 138.33B 48.25 8.65 0.00%
Becton Dickinson & Co (BDX) 57.96B 52.02 2.35 1.97%
Alcon (ALC) 35.92B 54.24 1.64 0.48%
ResMed (RMD) 33.14B 21.46 5.57 1.04%
Medline (MDLN) 32.55B 57.52 2.76 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★★☆ Fair value13.50 Economic moatNone UncertaintyVery High Capital allocationStandard

Trading 62.8% below Morningstar's fair value estimate.

Analyst note

Dentsply Sirona delivered 8% and 20% declines in revenue and adjusted EPS, respectively, during the third fiscal quarter, coming in behind the FactSet consensus. Guidance for both was lowered, and shares traded down 13% afterhours on Nov 5.

Why it matters: We are again disappointed by Dentsply's inability to gain traction in any dental business segment. Setting Wellspect aside, up 11% and the company's only highlight over the past several years, the other three segments delivered poor results. Market conditions remain challenging, especially on the equipment side, but we think Dentsply's presence on the premium side of the market makes segments like CTS (down 12%) more sensitive to macro pressure. By our analysis, Dentsply's results this quarter rank at the bottom of the peer bucket in terms of relative strength. With nine months of results under its belt, Dentsply has shown no meaningful signs of progress that convince us the firm is turning a corner. The decline in all three dental segments has accelerated for the third consecutive quarter. We heard some green shoots on the call, like US commercial expansion and improved customer conversions, but the outlook update implies similar challenges will drag in the fourth quarter, too.

The bottom line: We lower our fair value estimate to $13.50 per share from $14.00 after trimming both our fourth-quarter and 2027 estimates. The firm's 2026 EPS estimate was lowered 14% at the midpoint, despite third-quarter profits benefiting from one-time inventory-related items. Our 2026 EPS estimate for the base business, excluding these and tariff refund benefits, is $1.10, which is more than 30% lower than last year. While we still think shares look cheap, we highlight our Very High Uncertainty Rating, which reflects Dentsply's ongoing challenges and risks around near-term cash flows and recovery timing.

Fair value

We are lowering our fair value estimate to $13.50 per share from $14.00 after trimming both our fourth-quarter and 2027 estimates.

Our 2026 adjusted EPS estimate for the base business, excluding tariff refund benefits in the second quarter ($0.17 tailwind) and the one-time inventory benefit in the third quarter ($0.13), is $1.10, more than 30% lower than last year. Dental segments remain challenged across the board, and we model a low-single-digit decline in both EDS and orthodontic/implants and a high-single-digit decline in CTS in 2026. Wellspect remains one bright spot for the firm, and we model 10% growth for the business, but the segment makes up only about 10% of Dentsply's total revenue, and the strong performance isn't enough to offset the overall sales decline of 5% for the year.

Our long-term sales assumption relies on continued innovation by the firm—which allocates 4% of sales to research and development—as well as long-term macro trends including an aging population and an increasing demand for aesthetic dentistry. We forecast low-single-digit sales growth for the equipment business, comprising treatment centers and imaging equipment, and the consumables business. We think the CAD/CAM business is poised to grow at a higher rate—midsingle digits over our forecast period—as more dentists adopt digital solutions and more patients seek chairside solutions that require less seat time. While we believe less than 20% of dentists in the US have full chairside solutions at their practices, with the remaining workforce employing dental labs as needed, we expect this number to climb. Dentsply Sirona might not fully reap the benefits of this trend, given that it mainly plays in the premium category and there are many value-based brands, but we still expect it to enjoy tailwinds from the increasing prevalence of digital dentistry. We expect the firm’s orthodontic and implant solutions to grow by mid- to high single digits over the next five years. While clear aligners make up roughly 10% of all orthodontic case starts today, we expect this number to climb over the next five years as prospective patients learn the benefits of clear aligners and their clinical viability. For implantology, we expect healthy top-line growth thanks to the firm’s investment in this category. Recently, the Chinese implant market and its volume-based procurement policy have raised many uncertainties. VBP tenders volume for an entire market to the lowest-priced seller, and we have seen this policy reduce the average selling price for implants by 40%-50%. Dentsply Sirona was among many healthcare firms affected by this policy, but we believe the pricing headwind is offset by the extra volume that the firm won through the process.

We expect a moderate year-over-year margin increase as high-margin businesses like implant and orthodontic solutions continue to make up a larger portion of sales and the firm lowers operating expenses. Management has been very vocal about wanting to better integrate Dentsply and Sirona and has listed a number of actions that could help achieve this: optimize its enterprise resource planning systems to one platform, simplify the manufacturing footprint, and reduce distribution centers. While these efforts could take a number of years to complete, we believe they will harmonize the firm and help drive productivity and efficiency.

Economic moat

We do not believe Dentsply Sirona has an economic moat because we do not believe the company possesses any structural advantages sufficient to generate excess returns over the next 10 years.

Dentsply Sirona is one of the largest manufacturers of dental equipment and supplies. The firm has a strong presence in dental CAD/CAM and has long reaped the benefits of being a first mover. It offers some of the most technologically advanced products on the market, including its flagship Cerec, a full chairside workflow for restorations, implantology, and orthodontics that enables a complete procedure in a single visit. Many of the firm’s products play in the premium category and boast high speed, accuracy, and accessibility. However, the wide adoption of CAD/CAM in dentistry over the last two decades has led to an emergence of new competitors, making the industry highly fragmented and competitive. In the intraoral scanner market, for example, we see attractive offerings from 3Shape, Medit, and Align Technology, with their scanners at prices 25%-40% lower than Dentsply Sirona’s latest Primescan. While we believe Dentsply Sirona’s Cerec system is valuable if a doctor owns an entire suite of machines under the workflow, it loses its competitive advantage if only parts of the portfolio are adopted, since it is largely a closed system. For instance, Primemill can only accept files that were scanned using Primescan, unless scans from a third-party scanner are converted to a Cerec-compatible format using the firm’s inLab software. We believe this process is too cumbersome and takes away from the convenience aspect that Cerec emphasizes, swaying doctors to either fully adopt Dentsply Sirona’s solutions or go with different options. Furthermore, we believe promoting the full Cerec workflow becomes increasingly difficult as its premium price tag targets the very high end of dental practices, and competitors like Carestream and Planmeca offer comparable open-system products at cheaper prices. We think that the growth of lower-priced competitors will continue to erode intangible competitive advantages that specialty players like Dentsply Sirona once possessed.

In orthodontics and implantology, we think Dentsply Sirona faces stiff competition and will struggle to displace category leaders. In orthodontics, the firm offers SureSmile, a doctor-led clear aligner solution that Dentsply acquired through its purchase of OraMetrix in 2018. However, we still see a challenging landscape as Invisalign, a clear aligner from Align Technology, has 90% of the US market. SureSmile’s 2024 annual revenue was about $250 million compared with Invisalign’s $3.2 billion. In implantology, a fragmented market with a few key players, we think Dentsply Sirona faces stiff competition. Straumann controls roughly 30% of the global implant market, and Envista holds the second-highest share at around 25%. Henry Schein and Dentsply Sirona are the next-largest players, both controlling a low-teens share of the market, but we believe Dentsply Sirona has lagged its peers in terms of innovation. It has made efforts to improve its implant business by launching PrimeTaper in 2021 and OmniTaper in 2023 as well as promoting education among doctors and its salesforce, but we still think its portfolio lacks technical superiority to merit a moat.

Bull case

Expertise and leadership in digital dentistry position Dentsply to enjoy secular tailwinds as more doctors move away from dental labs and adopt chairside solutions.

Growing adoption of dental care in key European markets and emerging countries enables Dentsply to widen its end markets and drive growth across regions.

Management has restructured to better integrate Dentsply and Sirona and create a more harmonious and simplified operation, which could lower operating expenses over the long term.

Bear case

Dentsply’s CAD/CAM products mainly play in the premium category. A wide adoption of digital dental solutions has led to more affordable options on the market, making the space more fragmented and competitive.

Market leaders in implantology and orthodontics have decades of experience and are well connected with professionals, making it difficult for Dentsply to displace them and garner share.

US dental market weakness continues to weigh on Dentsply's growth, and the region's slow recovery could continue to damp the firm's stock.

By Keonhee Kim

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Dentsply Sirona discussion 0 comments

Add a comment